EMA/483374/2013

European Medicines Agency decision

P/0200/2013

of 2 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (hydrochloride), (EMEA-001176-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0200/2013

of 2 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for pitolisant (hydrochloride), (EMEA-001176-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0194/2012 issued on 24 August 2012,

Having regard to the application submitted by Bioprojet Pharma on 25 April 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 July 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pitolisant (hydrochloride), film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Bioprojet Pharma, 9 Rue Rameau, 75002 – Paris, France.

Done at London, 2 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/273172/2013 Corr.

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001176-PIP01-11-M01

Scope of the application

Active substance(s):

Pitolisant (hydrochloride)

Condition(s):

Treatment of narcolepsy

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bioprojet Pharma

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bioprojet Pharma submitted to the European Medicines Agency on 25 April 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0194/2012 issued on 24 August 2012.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 22 May 2013.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 19 July 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of narcolepsy

The waiver applies to:

- All subsets of the paediatric population from birth to less than 6 years of age;
- for film-coated tablet oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: treatment of narcolepsy

2.1.1. Indication(s) targeted by the PIP

Treatment of narcolepsy with or without cataplexy.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet, oral use.

2.1.4. Measures

Area	Number of measures	Description
Quality	1	**Measure 1:** Development of scored tablets designed to deliver 1/4 of the tablet strength accurately.
Non-clinical	1	**Measure 2:** Neonatal and juvenile (pre and post weaning) toxicity study in the rat by the intraperitoneal route.
Clinical	2	**Measure 3:** Multi-centre, single dose trial to evaluate pharmacokinetics of pitolisant in children from 6 to less than 18 years with narcolepsy. **Measure 4:** Double blind, multicentre, randomised, placebo controlled add-on to Sodium oxybate trial to evaluate safety and efficacy of pitolisant in children from 6 to less than 18 years with narcolepsy with/without cataplexy.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2015
Deferral for one or more studies contained in the paediatric investigation plan:	Yes